Neues zum Familiären Mittelmeerfieber

Zusammenfassung

Das Familiäre Mittelmeerfieber (FMF) ist die häufigste hereditäre autoinflammatorische Erkrankung und manifestiert sich in der Regel bereits im Kindesalter. Obwohl vor allem Menschen aus dem östlichen Mittelmeerraum betroffen sind, ist die Diagnose FMF auch in Deutschland durch Zuwanderung verschiedener Bevölkerungsgruppen keine Rarität mehr.

Mehrere Artikel fassen die zunehmenden Erkenntnisse zur Pathophysiologie, Diagnostik und Therapie dieser Erkrankung zusammen (11, 13). Ziel dieses Artikels ist es, neben dem bereits bekannten Wissen zum FMF vor allem die seit 2013 hinzugekommenen wesentli-chen Arbeiten zusammenzufassen.

Summary

Familial Mediterranean Fever (FMF) is the most common hereditary autoinflammatory syndrome often manifesting during childhood. Although the disease is more frequent' in east mediterranean countries like Turkey, Israel or Armenia, there are also patients presenting with FMF in Germany. Here we summarize studies and papers since 2013 contributing to the pathophysiology, diagnosis and therapy.

Schlüsselwörter

Familiäres Mittelmeerfieber - FMF - Autoflammation - Amyloidose

Keywords

Familial Mediterranean Fever - FMF - autoinflammation - amyloidosis

• Literatur

• 1 ClinicalTrials.gov, Identifikationsnummer: NCT02059291. www.clinicaltrials.gov
• 2 Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90: 797-807.
• 3 Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF - definition, causes and suggested solutions. Clinical and experimental rheumatology 2008; 26 (Suppl. 50) Suppl S49-51.
• 4 Ben-Zvi I, Livneh A. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Isr Med Assoc 2014; 16: 271-273.
• 5 Brik R, Butbul-Aviel Y, Lubin S. et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol 2014; 66: 3241-3243.
• 6 Chae JJ, Cho YH, Lee GS. et al. Gain-of-Function Pyrin Mutations Induce NLRP3 Protein-Independent Interleukin-1 beta Activation and Severe Autoinflammation in Mice. Immunity 2011; 34: 755-768.
• 7 Cronstein BN, Molad Y, Reibman J. et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. The Journal of clinical investigation 1995; 96: 994-1002.
• 8 Federici S, Sormani MP, Ozen S. et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the rheumatic diseases 2015; 74: 799-805.
• 9 Giancane G, Ter Haar NM, Wulffraat N. et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the rheumatic diseases. 2015
• 10 Hentgen V, Grateau G, Kone-Paut I. et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Seminars in arthritis and rheumatism 2013; 43: 387-391.
• 11 Kallinich T. Neues zum Familiären Mittelmeerfieber. Arthritis und Rheuma 2013; 13: 379-385.
• 12 Kallinich T, Haffner D, Niehues T. et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119: e474-483.
• 13 Kallinich T, Wittkowski H. Familiäres Mittelmeerfieber, 1. Aufl. Bremen: UNI-MED Verlag. 2014
• 14 Kallinich T, Wittkowski H, Keitzer R. et al. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Annals of the rheumatic diseases 2010; 69: 677-682.
• 15 Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012; 28: 137-161.
• 16 Livneh A, Langevitz P, Zemer D. et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis and rheumatism 1997; 40: 1879-1885.
• 17 Marek-Yagel D, Berkun Y, Padeh S. et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis and rheumatism 2009; 60: 1862-1866.
• 18 Medlej-Hashim M, Delague V, Chouery E. et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC medical genetics 2004; 5: 4
• 19 Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2014; 10: 135-147.
• 20 Ozen S, Demirkaya E, Duzova A. et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Annals of the rheumatic diseases 2014; 73: 897-901.
• 21 Paschke S, Weidner AF, Paust T. et al. Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. Journal of leukocyte biology 2013; 94: 1091-1096.
• 22 Shinar Y, Obici L, Aksentijevich I. et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Annals of the rheumatic diseases 2012; 71: 1599-1605.
• 23 Shohat M, Halpern GJ. Familial Mediterranean fever - a review. Genetics in medicine: official journal of the American College of Medical Genetics 2011; 13: 487-498.
• 24 Shohat M, Magal N, Shohat T. et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. European journal of human genetics: EJHG 1999; 7: 287-292.
• 25 Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. The American journal of medicine 1967; 43: 227-253.
• 26 Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B. et al. The effect of colchicine on pyrin and pyrin interacting proteins. Journal of cellular biochemistry 2012; 113: 3536-3546.
• 27 Touitou I, Sarkisian T, Medlej-Hashim M. et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis and rheumatism 2007; 56: 1706-1712.
• 28 Tunca M, Akar S, Onen F. et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005; 84: 1-11.
• 29 Twig G, Livneh A, Vivante A. et al. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Annals of the rheumatic diseases 2014; 73: 704-709.
• 30 Wittkowski H, Frosch M, Wulffraat N. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis and rheumatism 2008; 58: 3924-3931.
• 31 Xu H, Yang J, Gao W. et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 2014; 513: 237-241.
• 32 Yalcinkaya F, Ozen S, Ozcakar ZB. et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009; 48: 395-398.
• 33 Yilmaz S, Cinar M, Simsek I. et al. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2015; 54: 564-565.